CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present...
Hence then, the article about harbour biomed to present phase ii data of hbm4003 and tislelizumab combination in mss metastatic colorectal cancer at esmo 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025 )
Also on site :
- Can New Windows Increase Your Home’s Value Before You Sell? What Appraisers Look For
- I Assumed My Daughter’s Friend Was Busy All Summer. When School Started, We Both Learned the Truth.
- I Waited 36 Years to Tell Brian Austin Green Why I Might Still Be Grounded Because of Him… His Reaction? Worth the Wait!